WTO members to stretch deadline on extending TRIPS decision to COVID tests, therapeutics

19 December 2022

World Trade Organization (WTO) members on Friday agreed to recommend that the General Council extends the December 17 deadline established to decide on whether the TRIPS Decision adopted in June at the 12th WTO Ministerial Conference should be extended to COVID-19 diagnostics and therapeutics.

At a formal meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS), members agreed on the content of the report that the chairman, Ambassador Lansana Gberie of Sierra Leone, will submit on this issue to the General Council, scheduled to meet on December 19-20.

The report reads as follows:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK